BioNTech co-founders Özlem Türeci (L) and Uğur Şahin (Horst Galuschka/picture-alliance/dpa/AP Images)
June 5, 2022 12:30 PM EDTUpdated June 6, 08:27 AM
R&D

#AS­CO22: BioN­Tech says mR­NA vac­cine safe in 15 of 16 pa­tients with dead­ly pan­cre­at­ic can­cer

Kyle LaHucik

Senior Reporter

CHICA­GO — Pan­dem­ic vac­cine break­out BioN­Tech is back with more da­ta on its in­di­vid­u­al­ized mR­NA can­cer jab known as au­to­gene ce­vumer­an in the most com­mon …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

No­vo Nordisk’s once-dai­ly he­mo­phil­ia drug Al­he­mo ap­proved in US

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

GSK's Ze­ju­la-Jem­per­li com­bo in ovar­i­an can­cer hits pri­ma­ry end­point, miss­es on over­all sur­vival

A service from the Financial Times